Liminatus Pharma Inc

Research Liminatus Pharma Inc (LIMN) on Bullrun: market cap USD 206.89M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

TickerLIMN
ExchangeNASDAQ
CountryUnited States
SectorHealthcare
IndustryBiotechnology
CurrencyUSD
Market capUSD 206.89M
Financial periodQ1 2026
RevenueUSD 0
Net income-USD 11.00M
Free cash flow-USD 11.83M

Valuation Snapshot

latest market cap is USD 206.89M.

Five-year financial history

Year	Revenue	Net income	Free cash flow	Gross margin	Diluted EPS	Cash	Total debt	Equity
FY2025	n/a	-USD 10.21M	-USD 9.98M	n/a	-0.43	USD 337.66K	USD 1.44M	-USD 9.81M
FY2024	n/a	-USD 3.55M	USD 2.32B	n/a	-0.2	USD 0	USD 19.97M	-USD 19.34M

Valuation history

Year	Snapshot date	Market cap	P/E	Dividend yield	Annual dividend/share
2026	2026-08-25	USD 206.89M	n/a	n/a	n/a
2025	2025-12-31	USD 16.51M	n/a	n/a	n/a

About Liminatus Pharma Inc

Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer. The company was founded in 2018 and is based in Cerritos, California.

Related stock research

United States stocks United States Healthcare stocks A-Z stock index

Other Healthcare stocks

Adicet Bio Inc (1IJ) Cartesian Therapeutics, Inc. (1S70) QUOIN PHARMACEUT.ADR5000 (2EB0) Aardvark Therapeutics Inc (AARD) Abeona Therapeutics Inc (ABEO) Acumen Pharmaceuticals Inc (ABOS) Absci Corp (ABSI) Arbutus Biopharma Corp (ABUS) ABVC BioPharma Inc (ABVC) Acadia Pharmaceuticals Inc (ACAD) Adicet Bio Inc (ACET) Achieve Life Sciences Inc (ACHV)

Frequently asked questions

What is Liminatus Pharma Inc's market cap?

Liminatus Pharma Inc's market capitalization is USD 206.89M.